Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
about
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesTargeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicineIntegration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential targetThe Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal ResearchDexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Alternative splicing enriched cDNA libraries identify breast cancer-associated transcriptsIn situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsTargeted therapies for killing tumor cells.Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progressionGenetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis.A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.Telomerase and cancer: time to move from a promising target to a clinical reality.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Immune therapy for breast cancer in 2010-hype or hope?Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery.Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.Fertility preservation and breast cancer: a reviewSynthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediateHER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein arrayTargeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-MethylselenocysteineAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to considerPotentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeDocetaxel/trastuzumab combination therapy for the treatment of breast cancer.Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agentsRoles of transforming growth factor-alpha in mammary development and disease.HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.Tumor detection and elimination by a targeted gallium corrole.Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
P2860
Q24650717-9839E057-2A0A-4D77-B970-4A560FF3EAB4Q26865436-D3CBD174-0986-4484-8179-5F0D14762D86Q28271520-B1A66C1C-3F70-4E53-BF0B-DF829E85D5C5Q28379612-93191CD9-0410-4A23-BACC-4DC2C58800EDQ28829762-8620E724-3708-4040-A83D-B63EE9CA1B1EQ33576337-AB34D45F-61E9-4ED1-940D-3684FCD7235EQ33661325-725B9A9E-C1A1-4CB6-812F-3AEBDE1B5284Q33787269-64660D9F-896C-4C93-8966-DEA9398F3FD2Q33812042-5184A5A2-DF91-4320-B710-6E652E2367EAQ33942895-2F654CD9-74D3-418B-9C13-1EF3CBDA81E7Q34014610-CFF78767-EE75-49C1-9D1C-92068F53382AQ34020212-00A861F9-FEF2-40DA-A7E3-CD6A019D8E9FQ34221898-660ECE42-1DA2-4B40-B204-263379B1BEF5Q34464335-EF2972B8-11AC-4CE2-8A05-8381DB38FA9EQ34469271-DF27176B-F49C-495B-A56B-B178D1847AC8Q34541467-B766ADAE-3DA0-409B-81CB-FC3BC2E46DD5Q34698633-8F861427-D6E2-4285-9837-8100F8791AA5Q34973413-CEDFEAB9-FC50-4B70-8B1D-B9AC6D16397BQ35106163-148F7E4C-78AE-40F3-B630-5C5D959C91FCQ35180943-8FC0AAA5-EE0E-48B1-B010-D6A788B9A30AQ35184966-037A0CA2-C902-4A69-A993-CCD4844E31ABQ35208201-AC31FF9C-C42F-4A35-A00C-FCCD5A04D733Q35222776-273626B3-2A91-4429-9677-8B0F09D3668BQ35237773-DC512696-23E9-4584-B712-EB4722E59CE3Q35583779-75CFAE45-7F35-4FDA-85DC-12A6A6D3875CQ35629436-664DA6DD-BFFB-4F14-B50E-A0AEF3333859Q35892041-CDDA56D1-D90F-4E2B-A3E7-B0B091C3F9CCQ35892045-212D8255-8BAA-4215-94FC-885943E3F6CDQ36222001-9E6A261B-5D4F-4D3A-9D56-A2F87EC1188BQ36297064-66247368-6C17-4078-8DDD-CBD43566FC96Q36311218-6201B36C-97C5-43C0-9661-8E8AFB998057Q36609570-4C37ECB6-9F10-4274-9251-E6E66FB8554EQ36730394-83D1D838-4A44-461E-B517-E420DAC010EBQ36775982-FB2A391E-B506-4199-9154-BCF3662CA03EQ37037476-01E2E7FD-75AA-4F45-8003-695ACAB2961AQ37073441-06082BB5-E6B0-49DE-94E5-003B42619754Q37076842-8A6E79F0-F098-4932-BFDD-F015411C7C0DQ37158974-BF0241E9-77B9-49F0-90F9-DCCCB27ADE65Q37186412-01747609-0A36-4611-8FD6-FA9481CD278CQ37191051-09D12042-577D-4400-9FAF-4B56A6DF90CE
P2860
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@ast
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@en
Rationale for trastuzumab
@nl
type
label
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@ast
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@en
Rationale for trastuzumab
@nl
prefLabel
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@ast
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@en
Rationale for trastuzumab
@nl
P1433
P1476
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
@en
P2093
P356
10.1016/S0093-7754(01)90188-5
P433
P577
2001-02-01T00:00:00Z